Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
- Conditions
- Registration Number
- NCT02422979
- Lead Sponsor
- Rakuten Medical, Inc.
- Brief Summary
This is a two-part clinical study of patients with recurrent Head and Neck Cancer (HNC), who in the opinion of their physician, cannot be satisfactorily treated with surgery, radiation or platinum chemotherapy. The purpose of the study is to determine the safety and anti-cancer activity of various doses and repeated cycles of the experimental treatment using...
- Detailed Description
Photoimmunotherapy (PIT) is a new cancer targeted technology invented at the National Cancer Institute, USA. This clinical study evaluates the treatment of the experimental drug RM-1929 with Photoimmunotherapy (PIT).
...
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Patients must meet the following criteria to be eligible for study participation:
- Patients with recurrent squamous carcinoma of the Head and Neck, who in the opinion of their treating physician, cannot be satisfactorily treated with surgery, radiation, or platinum chemotherapy. Diagnosis must be confirmed by biopsy and histopathology.
- Patient must have received prior systemic platinum-based chemotherapy for treatment of their head and neck cancer, unless in the opinion of the medical oncologist, the use of platinum-based chemotherapy is contraindicated or not recommended, e.g., renal impairment, allergy to platinum compounds, age, liver disease, myelosuppression, neuropathy, hearing loss, etc.
- Patients must have life expectancy > 6 months based on investigator judgment.
- Male or female patients at least 18 years old. Female patients must not be pregnant or breast feeding and must be practicing a medically acceptable form of birth control, be sterile, or post-menopausal. Females of childbearing potential (FCBP) is defined as premenopausal women capable of becoming pregnant. This includes women who are post-menopausal for at least 12 months after the last menses. FCBP must agree to use a medically acceptable form of birth control during the study and for at least 6 months after discontinuation of Erbitux® or study medication. Females must agree not to breast feed during the study and for at least two months after discontinuation of Erbitux® or study medication. Male patients should be using a double barrier protection method that is a medically acceptable form of birth control during the study or be sterile.
- Patients must have an ECOG score of 0 - 2.
- Patient must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Patients with any of the following will be excluded from participation in the study:
- Patients with a history of significant Erbitux infusion reactions (≥ Grade 3).
- Patients on chemotherapy or Erbitux® therapy or radiation therapy within 4 weeks of enrollment.
- Tumor invading a major blood vessel (such as the carotid artery) unless the vessel has been embolized, stented or surgically ligated to prevent hemorrhage.
- Tumor is not clearly shown on a CT scan or clinically measurable.
- Location and extension of the tumor precludes an effective PIT.
- Patients with impaired hepatic function (ALP (hepatic), AST and/or ALT >3 times the upper normal limits, or total serum bilirubin > 2 mg/dL.
- Patients with impairment of renal function (serum creatinine >2 mg/dL).
- Unwilling or unable to follow protocol requirements.
- Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patient requires examinations or treatments within 4 weeks after study drug administration where they would be exposed to significant light, e.g., eye examinations, surgical procedures, endoscopy, etc.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Primary Outcome Measures
Name Time Method Part I: Photosafety (sunburn) Testing 1 month Determination of skin Minimal Erythema Dose (MED) following infusion of RM-1929
Part I: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) of RM-1929, whichever is lowest 1 month Determine the MTD or MFD of RM-1929
Part I: Adverse Event profile for each drug dose of RM-1929 1 month Assessment of safety of the combination of drug dose with low energy localized light irradiation
Part II: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) of a fixed drug dose with fixed light dose 1 month Determination of MTD or MFD of fixed drug dose with fixed light dose
Part II: Safety with repeat dosing 2 years or until death Safety parameters associated with repeat dosing
- Secondary Outcome Measures
Name Time Method Part II: Immunogenic response to RM-1929 2 months To assess antibodies to RM-1929 or cetuximab
Part I: Pharmacokinetics of RM-1929 and for both RM-1929 and unconjugated IRDye 700DX (Cmax, T 1/2, AUC, CL and Vss) 1 month Part I: Immunogenic response to RM-1929 2 month To assess antibodies to RM-1929 or cetuximab
Part II: Tumor Response 2 months Assessed using RECIST 1.1
Part I: Tumor response 2 months Document tumor response using response assessment in solid tumors version 1.1 (RECIST 1.1), including additional assessment of target lesion volumetrics
Part II: Tumor Reduction 2 months Evaluation by CT scans, clinical measurement, photographs, biopsies, symptom relief and ECOG performance
Part 1: Tumor reduction/necrosis 2 month Document tumor reduction/necrosis using Choi criteria
Trial Locations
- Locations (7)
UCSF Helen Diller Family Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
Rush University Cancer Center
🇺🇸Chicago, Illinois, United States
University of Oklahoma Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Centura Health Research Center
🇺🇸Denver, Colorado, United States
Virginia Piper Cancer Institute, part of Allina Health System
🇺🇸Minneapolis, Minnesota, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States